Gide

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gide

What is Gide? (Gliclazide)

Quick Facts

Property Description
Active ingredient Gliclazide
Form Tablet; Extended-release tablet (MR)
Pharmacological class Oral Antidiabetic Agent, Sulfonylurea
Common use Management of Type 2 Diabetes Mellitus
Origin Synthetic compound

Gide is a pharmaceutical product containing the active ingredient Gliclazide, designed to help manage blood sugar levels in individuals diagnosed with Type 2 Diabetes Mellitus. It is a prescription-only medicine (POM) intended for oral administration.

The foundational identity of Gide centers on its role as a single-entity, synthetic treatment used in the long-term metabolic control of hyperglycemia, the characteristic high blood sugar of Type 2 Diabetes. Gliclazide is a second-generation sulfonylurea, a classification that is clinically recognized for its improved metabolic profile compared to earlier compounds in its class.


What Type of Medicine is Gide and What Is It Made Of?

Gide is classified as an Oral Antidiabetic Agent belonging to the sulfonylurea pharmacological class. The active compound, Gliclazide, is a synthetic compound that functions as an insulin secretagogue. This medication is typically supplied as a solid dosage form, specifically an oral tablet and often as an extended-release tablet (Modified Release or MR form), which utilizes pharmaceutical excipients to facilitate a slow, sustained release.

Gliclazide is noted for its extra-pancreatic actions, including antioxidant and anti-platelet properties. This means Gliclazide offers a benefit beyond blood sugar control by helping to protect the small blood vessels often impacted by diabetes.


Gide's Primary Purpose: Managing Type 2 Diabetes Mellitus

The general purpose of Gide is to support the required metabolic control for effectively managing Type 2 Diabetes Mellitus by stabilizing glucose concentration in the bloodstream. A typical use scenario involves incorporating Gide into a regimen for non-insulin-dependent patients whose blood sugar remains high despite dietary management and lifestyle changes.

The therapeutic aim is achieved by Gliclazide's action as an insulin secretagogue, which directly encourages the specialized pancreatic beta-cells to release additional endogenous insulin. By improving insulin secretion, Gide helps reduce the chronic high blood sugar levels associated with the condition.

Regulatory References

  1. World Health Organization's List of Essential Medicines

What side effects are possible with Gide?

Possible Side Effects and Safety Information

The medicine Gide (Gliclazide) has an official safety profile that defines possible adverse reactions by frequency and the physiological system affected, strictly based on regulatory documents from government health authorities.


Frequency and System-Organ Classifications

The most frequently reported adverse reaction is Hypoglycaemia (low blood sugar), which is officially classified as common in prescribing information. Reactions grouped as uncommon include gastrointestinal disturbances, such as abdominal pain, nausea, vomiting, diarrhea, constipation, and dyspepsia.

Rare or isolated adverse effects are grouped into specific System-Organ Classes, including Hepatobiliary disorders (e.g., elevated liver enzymes, hepatitis, or cholestatic jaundice), Blood and lymphatic system disorders (e.g., changes in blood cell counts like thrombocytopenia or leucopenia), and Skin and subcutaneous tissue disorders (e.g., rash, pruritus).


Serious Reactions and Safety Constraints

The regulatory profile documents the risk of severe reactions, though rare, which include severe and prolonged Hypoglycaemia, and life-threatening bullous skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Isolated reports of serious liver impairment, including hepatitis, are also noted.

Official safety constraints state that Gide is contraindicated in cases of severe hepatic insufficiency or severe renal insufficiency due to the increased risk of prolonged hypoglycemia. The medicine is also restricted during pregnancy and breast-feeding. Time-related safety patterns indicate that transient visual disturbances may appear upon initiation of treatment due to the change in blood glucose levels.

Overdose and Emergency Response

The primary, documented consequence of a Gide overdose is hypoglycemia (dangerously low blood glucose), which is the principal physiological system affected. Official regulatory labeling lists typical manifestations such as tremor, sweating, confusion, dizziness, and headache. Overdose carries the risk of severe neurological outcomes, including convulsions, stupor, and coma, with documented potential for permanent brain damage if not corrected.

Immediate medical attention is required for any suspected overdose, and hospitalization is necessary for all severe or prolonged hypoglycemic episodes. Management consists of symptomatic and supportive measures, including the immediate administration of glucose, often intravenously for severe cases. Due to the drug's properties, regulators require that glucose administration may need to be continued for several days under prolonged hospital observation to monitor for recurrent low blood sugar.

Regulatory documentation also notes that elderly subjects and individuals with severe hepatic or renal insufficiency are particularly susceptible to serious, prolonged reactions. Treatment is guided by the absence of a specific pharmacological antidote.

Therapeutic Uses of Gide

The primary role of Gide is to provide supportive therapeutic benefit and symptomatic relief in clinical situations marked by heightened patient discomfort and disruptive manifestations. It is used to help ease the burden of challenging symptoms and supports general comfort during acute episodes.


Core Therapeutic Areas

Gide is commonly used across conditions presenting with acute episodes and those characterized by episodic or fluctuating manifestations. It helps address symptom clusters that may become intense or disruptive, especially those related to physical discomfort and systemic imbalance. The medication is generally applied in addressing pronounced and distressing manifestations.

Quick Fact: Support for Acute Discomfort Gide is often used when symptoms intensify and supportive relief is needed, assisting with temporary physiological strain.

Functional Support and Symptom Moderation

It is relevant in contexts marked by increased discomfort or tension, which often accompany these conditions. The benefit is offering symptomatic support that may assist patients with managing difficult episodes and contributes to easing the overall symptom load. Gide is generally relevant in conditions where functional stability may become affected by symptoms that are temporarily overwhelming, and may assist with maintaining comfort when symptoms are more noticeable.

Eligibility and Restrictions for Use

Gide (Gliclazide) is an oral antidiabetic medicine officially indicated for adults with Type 2 Diabetes Mellitus. Eligibility is determined by strict regulatory rules defining the populations for whom use is prohibited or restricted.

Contraindicated Populations (Must Not Use) Age-Group Restrictions
Type 1 Diabetes Mellitus Pediatric Population (<18 years) is not recommended; safety and efficacy are not established [Source 1.4, 2.4].
Diabetic Ketoacidosis or diabetic pre-coma/coma Adults (≥18 years) are the approved population [Source 2.4].
Severe Renal Insufficiency (Severe Kidney Failure) Older Adults (≥65 years) may be prescribed the same regimen but require careful monitoring [Source 2.5].
Severe Hepatic Insufficiency (Severe Liver Failure) Pregnancy: Not recommended; insulin is preferred [Source 1.5, 2.5].
Lactation (Breastfeeding) Lactation: Contraindicated [Source 2.3, 2.4].
Known Hypersensitivity to Gliclazide, sulfonylureas, or sulfonamides [Source 2.3].

Eligibility is also subject to condition-specific restrictions. Use is permitted in mild to moderate renal impairment but requires close patient monitoring [Source 2.4]. Use is restricted to patients with regular food intake, including breakfast, due to the risk of hypoglycemia [Source 2.2]. Caution should be used for patients with G6PD deficiency, and a non-sulfonylurea alternative should be considered [Source 2.2].

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Gide

This profile summarizes the officially documented interactions for Gide (Gliclazide) based solely on government regulatory prescribing information.


Interaction Scope

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions Agents Potentiating Hypoglycemia: Other antidiabetic agents, Beta-blockers, NSAIDs, MAO inhibitors, ACE inhibitors. Agents Causing Hyperglycemia: Glucocorticoids, Danazol, \beta-2 agonists, Oestrogens/Progestogens.
Specific interacting medicines (if explicitly listed) Contraindicated: Miconazole. Specific Potentiators: Fluconazole, Clarithromycin, Phenylbutazone. Specific Reducer: Rifampin.
Mechanistic basis of interactions (only if stated in label) Potentiation: Displacement from plasma proteins, reduced elimination, or additive pharmacodynamic effects. Reduction: Increased metabolism/enzyme induction (e.g., Rifampin, St. John's Wort).
Timing-based interaction rules (if applicable) No mandatory timing separation rules (e.g., "administer X hours apart") are explicitly stated in official labeling.
Population-specific interaction notes (if applicable) Fluoroquinolones carry an increased risk of blood glucose disturbances (dysglycaemia) especially in elderly patients.
Interaction-related restrictions Mandatory Avoidance: Alcohol (due to increased hypoglycaemic reaction risk) and Miconazole. Caution Required: St. John's Wort (reduces Gliclazide exposure).

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation Statement
Interaction severity classification (as defined in official documents) Contra-indicated combination (Miconazole). Combinations not recommended/requiring avoidance (Alcohol, Phenylbutazone, Danazol).
Regulatory basis (EMA / FDA / etc.) Based on formal interaction tables and statements found in the Summary of Product Characteristics (SmPC) and equivalent national regulatory documents.
Interaction-context constraints (as defined in official documents) Interactions are primarily classified by the effect on blood glucose: Potentiation of Hypoglycaemic Effect or Reduction of Hypoglycaemic Effect.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Miconazole (systemic or oromucosal gel) is contraindicated due to the risk of severe potentiation of the blood sugar lowering effect.
  • The effect of Gide is potentiated by agents that interfere with its clearance or provide an additive pharmacodynamic effect, including Fluconazole, Beta-blockers, and ACE Inhibitors.
  • The therapeutic efficacy is reduced by agents that promote hyperglycemia or increase Gliclazide's metabolism, such as Glucocorticoids, Rifampin, and Danazol.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the Gliclazide interaction structure based on potentiation or reduction of its blood sugar lowering action. This structure emphasizes substances that alter Gliclazide's exposure, such as Phenylbutazone via protein binding displacement or St. John's Wort via enzyme induction, as well as those with additive effects on glucose control. The profile highlights mandatory avoidance of Miconazole and Alcohol.

Mechanism of Action

Gide, containing Gliclazide, exerts its primary effect through direct interaction with the Sulfonylurea Receptor 1 ( SUR1), a subunit of the ATP-Sensitive Potassium ( K ATP) channel complex on pancreatic beta-cells. Gliclazide acts as an allosteric blocker, forcing the K ATP channel to close.

This molecular blockade halts the efflux of potassium ions ( K^+), rapidly depolarizing the cell membrane. The depolarization opens voltage-dependent calcium ( Ca^2+) channels, and the subsequent Ca^2+ influx serves as the intracellular signal for the beta-cell to initiate the exocytosis of stored insulin granules. This mechanism increases endogenous insulin secretion and modulates the immediate, first-phase insulin dynamics essential for physiological regulation of glucose.

Furthermore, Gliclazide exhibits SUR1 selectivity, resulting in reduced interaction with K ATP channels in cardiac and vascular tissues, thereby localizing the depolarizing activity to the pancreatic pathway. It also engages extra-pancreatic mechanisms involving antioxidant activity and the modulation of platelet adhesion within the vasculature.

Dosage and Administration Information

How to Use Gide (Gliclazide)

The administration of Gliclazide (Gide) involves specific protocols regarding the route, schedule, and handling of the medication.


Official Administration Guidelines

Instruction Detail
Route of administration Oral administration (swallowed).
Dosing schedule The dose varies by formulation. The Modified Release (MR) starting dose is typically 30 mg once daily, with a maximum of 120 mg daily. The Immediate Release (IR) maximum dose is 320 mg daily, often administered in divided doses.
Timing in relation to meals The medication is taken with food, specifically coinciding with a major meal such as breakfast.
Preparation requirements The tablet is swallowed whole with water.
Special procedural conditions Do not crush, chew, or divide the Modified Release tablets.
Missed-dose rules If a dose is missed, the dose is not doubled the following day; the regular schedule is resumed.

Usage Patterns and Population-Specific Rules

Treatment with Gliclazide is intended for long-term use for metabolic control, with dose adjustments (titration) typically occurring at intervals of at least one month based on clinical response.

For older adults and those at higher risk, treatment is typically initiated with the minimum effective starting dose. Patients with mild to moderate renal impairment generally follow the same dosing regimen as those with normal renal function, provided their condition is monitored closely. Use in children and adolescents is not established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gide

Evidence for Use in Managing Type 2 Diabetes Mellitus (T2DM)

Research on Gide (Gliclazide) has been conducted primarily using Randomized Controlled Trials (RCTs). These trials examined what outcomes related to systemic or functional imbalance associated with Type 2 Diabetes were monitored in the research. Researchers monitored key metrics like Glycated Hemoglobin ( HbA1 c) and blood glucose levels, comparing results against placebo or other agents used in the research.

Studies on Outcomes Beyond Blood Sugar Control (Vascular Effects)

Beyond measuring changes in blood sugar, specific large-scale studies was studied for its potential association with long-term diabetes complications. Researchers tracked whether the use of Gide was associated with differences in the development of microvascular complications, such as kidney damage (diabetic nephropathy), and severe macrovascular events, which include heart attack or stroke. One major long-term trial described patterns where the incidence of severe kidney-related events (diabetic nephropathy progression) in the Gliclazide group differed from the standard care group.

Long-Term Studies and Durability of Response

Research has explored the patterns of Gide over defined time intervals ranging from a few months up to several years. The largest trials used in research exploring how symptoms change over time included follow-up periods of approximately five years, with some observational data extending even longer. The studies contribute to understanding the measured changes in blood sugar levels observed over the period of long-term tracking.

What Is Still Uncertain About Gide

Although a large body of evidence exists, the research highlights several areas where certainty remains low or where more investigation is needed. Follow-up durations were limited in many smaller trials, and the evidence quality varies across studies due to methodological differences. Therefore, the research provides insight into short-term changes but does not definitively predict all long-term individual outcomes. The existing findings help contextualize what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Gide (FAQ)


Q: How long does it typically take for a person to notice the effects of Gide?

According to official product information, the active ingredient in Gide is completely absorbed and reaches its peak levels in the bloodstream several hours after being taken. Gide works by immediately restoring the first peak of insulin release from the pancreas in response to glucose. Maintaining long-term control of blood sugar, as often measured by A1c, is generally achieved through consistent use and prescribed dose adjustments.


Q: What happens if I miss a scheduled time to take Gide?

If a dose of Gide is missed, regulatory guidance is to skip that dose entirely. The guidance is to then take the next dose at its usual scheduled time. Official documents specifically caution against taking two doses to make up for a single forgotten dose, as this could significantly increase the risk of developing low blood sugar (hypoglycemia).


Q: Does Gide cause weight gain or weight loss?

While individual results vary, weight gain is a possible effect that has been cited in clinical discussion regarding second-generation sulfonylureas, the class Gide belongs to. Weight changes may be reported in patient groups as a possible side effect. Concerns about weight changes can be addressed by a healthcare professional.


Q: Can Gide affect blood pressure?

Gide's main function is to lower blood sugar. However, low blood sugar (hypoglycemia) is a common side effect, and the body's protective response to hypoglycemia can trigger temporary physical changes. These changes may include a fast heart rate or, in some cases, temporary spikes in blood pressure.


Q: Does Gide have any known long-term side effects?

Official safety profiles note that Gide may be associated with rare but serious reactions that can occur over time, such as liver impairment and changes in blood cell counts. Large-scale studies have focused on the long-term patterns of Gide use, specifically tracking its association with complications related to diabetes, like kidney damage and cardiovascular events.


Q: Is Gide safe to use during pregnancy, according to official documents?

Official regulatory documents state that Gide is not recommended for use during pregnancy. Due to the need for strict glucose control during pregnancy, insulin is often used as an alternative treatment, as noted in regulatory guidelines.


Q: What does the research say about Gide's effectiveness?

Clinical studies have examined Gide’s ability to improve long-term metabolic control, primarily by monitoring key metrics like Glycated Hemoglobin ( HbA1 c) and blood glucose levels. Research also includes studies that explored Gide’s patterns of use and its long-term association with microvascular complications, such as kidney damage.


Q: Can Gide affect driving or operating machinery?

Official warnings state that Gide may cause symptoms of low blood sugar (hypoglycemia), which can include dizziness or drowsiness and may slow reaction time. Official warnings note that patients should be careful driving or operating machinery until they understand how the medicine affects them.


Q: Can Gide be crushed or split?

The Modified Release (MR) tablet formulation of Gide must not be crushed, chewed, or divided, as this would prevent the medicine from releasing slowly into the body as intended. Any instructions for administering the Immediate Release (IR) formulation should be followed as directed by a healthcare provider.


Q: Do you need to take Gide at the exact same time every day?

Gide (especially the once-daily MR formulation) is designed to be taken at a consistent time each day, specifically coinciding with a major meal such as breakfast. The consistent timing of the dose with the same meal each day is intended to help maintain stable blood sugar levels and reduce the risk of hypoglycemia.


Q: What kind of monitoring is typically done while taking Gide?

Treatment with Gide requires ongoing monitoring of blood glucose and Glycated Hemoglobin ( HbA1 c) levels, as regulatory bodies state the dose must be adjusted based on these measures. Additionally, liver and kidney function tests are typically required because severe impairment in these organs is a known contraindication for Gide.


Q: Is Gide similar to other common medicines used for this condition?

Gide belongs to the pharmacological class known as second-generation sulfonylureas. This group of oral medicines is used to manage Type 2 Diabetes and acts by stimulating the pancreas to produce more insulin. This mechanism is similar to other drugs within the sulfonylurea class.


Q: What are the most commonly reported side effects of Gide?

The most frequently reported adverse effect in official documents is Hypoglycaemia (low blood sugar), which is classified as common. Gastrointestinal disturbances are also commonly reported, and this group includes abdominal pain, nausea, vomiting, diarrhea, and constipation.


Q: Are there any known foods or drinks that should be avoided while taking Gide?

Official regulatory documents specifically highlight Alcohol consumption as a mandatory avoidance. The combination of Gide and alcohol is associated with an increased risk of severe hypoglycemic reactions, which is why official regulatory guidance advises avoidance.


Q: Can Gide affect sleep patterns?

While not listed as a primary side effect, low blood sugar (hypoglycemia) is a common adverse reaction to Gide. The official symptoms of hypoglycemia can include effects such as nightmares or difficulty sleeping, which may change a person’s typical sleep patterns.


Q: Is Gide available as a generic medicine?

The active ingredient in Gide is Gliclazide. Gliclazide is widely available in generic forms in many regions. Gide is a specific brand name for products containing this active ingredient.


Q: Does Gide cause mood changes or depression?

Changes in mood, such as depression, are not classified as common reactions in Gide's official safety profile. However, symptoms that could affect mood, like poor concentration or unusual weakness, are sometimes reported as potential signs to monitor during treatment.


Q: Can Gide be taken with herbal supplements?

Regulatory guidance specifically advises caution or avoidance with the herbal remedy St John’s Wort, as it may affect how the body metabolizes Gide. Due to limited data, there is generally not enough specific information in official documents to confirm the safety of most other herbal supplements when combined with Gide.


Q: Is Gide considered a newly developed drug?

No. Gide’s active ingredient, Gliclazide, is classified as a second-generation sulfonylurea. This pharmacological class of medicines has been used in the treatment of Type 2 Diabetes for several decades and represents an established therapy option.


Q: Why do official documents advise caution when using Gide with certain heart medications?

Caution is advised when Gide is used with certain heart medications, such as Beta-blockers, because they can prevent the usual physical symptoms of hypoglycemia (low blood sugar). Specifically, these drugs can mask warning signs like tremor and fast heart rate, making a severe low blood sugar episode harder to detect.


Q: What happens when Gide interacts with over-the-counter pain relievers like ibuprofen?

Official documentation lists Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as agents that can potentially increase the blood sugar lowering effect of Gide, which raises the risk of hypoglycemia. Ibuprofen is a common example of an NSAID that is widely available over-the-counter.


Q: Can Gide interact with birth control pills?

Regulatory documents list Oestrogens/Progestogens as medicinal products that can potentially reduce the therapeutic efficacy of Gide. These hormones are the active ingredients in many types of birth control pills and may affect blood sugar control, potentially leading to hyperglycemia (high blood sugar).


Q: What is the difference between Gide and its main metabolite?

Gide (Gliclazide) is extensively processed in the liver before being eliminated from the body. Official pharmacological studies indicate that Gide does not produce any active metabolites that can be measured in the plasma, meaning the primary blood sugar lowering effect comes only from the original drug itself.


Q: Will Gide still work if I occasionally forget a dose?

Regulatory guidance advises against compensating for occasional missed doses by doubling up, as consistent adherence to the prescribed schedule is intended to help maintain the drug’s intended therapeutic effect.


Q: Is it possible to develop a tolerance to Gide over time?

Regulatory guidance and clinical experience note that Gide may stop working as effectively over a long period, a concept sometimes referred to as 'secondary failure' in medical literature. If this occurs, a healthcare provider may need to adjust the dose or add a different medicine to the treatment regimen.


Q: How does Gide affect kidney function?

Gide is primarily processed by the liver, and its inactive products are removed from the body via the kidneys. This profile is generally considered suitable for patients with mild to moderate kidney impairment, though severe kidney failure is a contraindication due to the increased risk of prolonged low blood sugar.


Q: What should I do if the side effects of Gide bother me?

Official patient information describes that a healthcare professional, such as a doctor or pharmacist, can be consulted if any side effects are severe, persistent, or bothersome. Patients are instructed to seek immediate medical attention if they experience signs of a severe allergic reaction or severe low blood sugar.


Q: Are there different strengths of Gide available?

Yes, Gide (Gliclazide) is available in different strengths and different formulations, including an Immediate Release (IR) tablet and a Modified Release (MR) tablet. The specific strength and type prescribed are based on the individual's needs.


Q: Do you need to stop taking Gide gradually?

Official patient guidance notes that treatment with Gide should not be stopped suddenly without consulting a healthcare provider. Abrupt discontinuation of Gide may cause blood sugar levels to increase significantly, which can be harmful.


Q: Is it common to feel tired when starting Gide?

While feeling tired is not listed as a common side effect itself, unusual tiredness or weakness is a potential symptom of hypoglycemia (low blood sugar). Since low blood sugar is a common adverse reaction when starting Gide, it may contribute to feelings of fatigue.


Q: Can Gide be used with other treatments for the same condition?

Yes, Gide is frequently used as part of a combination therapy approach for Type 2 Diabetes. Official interaction documents list other anti-diabetic agents that are often co-administered with Gide, which work together to potentiate the overall blood sugar lowering effect.


How should Gide be stored and disposed of?

Storage Requirements

The official storage conditions for Gide (gliclazide) tablets vary by formulation but typically require storage below 25°C or 30°C. Some Modified-Release (MR) forms may not require special temperature conditions. To maintain stability, the medicine must be kept in its original container and stored in a cool, dry place, protected from excessive heat, moisture, and direct sunlight. A mandatory safety requirement is to store Gide out of the sight and reach of children.

Disposal Instructions

Expired or unused Gide must be handled as pharmaceutical waste. Disposal must be carried out in accordance with local regulations and environmental protection rules. Regulatory instructions explicitly prohibit disposing of the medicine via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gide found in:

A-Z Index: